

LAC+USC Medical Center General Hospital Antibiogram January 2009-December 2009 Reported as % Susceptible		# of isolates	Penicillin	Oxacillin	Ampicillin	Ampicillin/ Subactam	Piperacillin/ Tazobactam	Aztreonam	Cefazolin	Cefepime	Cefotaxime	Ceftazidime	Ceftriaxone	Clindamycin	Erythromycin	Amikacin	Gentamicin	Tobramycin	Imipenem/ Cilastatin	Levofloxacin	Linezolid	Rifampin	Tetracycline	Trimethoprim/ Sulfamethoxazole	Vancomycin
Gram Negative Organisms																									
All isolates																									
<i>Acinetobacter baumannii</i>	35	--	--	--	51	66	--	--	48	--	45	--	--	--	79	57	62	60	51	--	--	45	57	--	--
<i>Acinetobacter calcoaceticus- baumannii complex</i>	124	--	--	--	51	63	--	--	44	--	33	--	--	--	88	54	57	59	47	--	--	46	46	--	--
<i>Escherichia coli</i>	2564	--	--	--	55	96	92	83	93	--	92	92	--	--	99	86	87	99	76	--	--	--	58	--	--
<i>Enterobacter aerogenes</i>	107	--	--	--	--	90	90	--	100	--	89	90	--	--	100	99	100	100	99	--	--	--	97	--	--
<i>Enterobacter cloacae</i>	244	--	--	--	--	86	85	--	98	--	81	83	--	--	100	97	98	99	96	--	--	--	89	--	--
<i>Klebsiella pneumoniae</i>	485	--	--	--	82	94	94	91	93	--	93	93	--	--	98	94	94	99	92	--	--	--	88	--	--
<i>Pseudomonas aeruginosa</i>	403	--	--	--	--	95	--	--	90	--	89	--	--	--	98	92	96	91	81	--	--	--	--	--	--
<i>Proteus mirabilis</i>	319	--	--	--	91	99	97	92	97	--	96	97	--	--	99	94	95	100	93	--	--	--	80	--	--
<i>Serratia marcescens</i>	77	--	--	--	--	98	100	--	100	--	100	96	--	--	100	100	98	100	98	--	--	--	98	--	--
ESBL producers: <i>Escherichia coli</i> :6%; <i>Klebsiella pneumoniae</i> :6%																									
Gram Positive Organisms																									
All isolates																									
<i>Staphylococcus aureus</i>	1064	--	54	--	--	--	--	--	--	--	--	--	--	84	46	--	98	--	--	53	100	98	--	97	100
OSSA	891	--	99	--	--	--	--	--	--	--	--	--	--	--	74	--	98	--	--	84	100	--	93	98	100
ORSA	1067	--	--	--	--	--	--	--	--	--	--	--	--	--	11	--	95	--	--	12	100	96	91	95	100
<i>Streptococcus pneumoniae</i>	38	81* 100**	--	--	--	--	--	--	100* 100**	--	100* 100**	--	--	86	--	--	--	--	100	--	--	94	97	--	--
Enterococcus spp.	249	--	--	84	--	--	--	--	--	--	--	--	--	--	--	--	83	--	--	--	100	--	--	--	100
<i>Enterococcus faecalis</i>	105	--	--	100	--	--	--	--	--	--	--	--	--	--	--	--	56	--	--	--	100	--	--	--	100
<i>Enterococcus faecium</i>	18	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	73	--	--	--	94	--	--	--	72

* Meningitis
 ** Non meningitis
 Gentamicin Synergy

Parenteral Antibiotic	Daily Cost*	Common Adult Dose	Formulary Restriction Status (refer to formulary updates)
Amikacin	\$	15 mg/kg q 24h	Treatment of documented organism resistant to gentamicin
Ampicillin	\$\$\$-\$\$\$\$	1-2 gm q 4-6h	Unrestricted
Ampicillin/Subactam	\$\$	1.5-3 gm q 6h	Infectious Diseases Service approval
Azithromycin	\$	500 mg q 24h	Unrestricted
Aztreonam	\$\$\$\$\$	1-2 gm q8h	Infectious Diseases Service approval
Cefazolin	\$	1 gm q 8h	Unrestricted
Cefepime	\$\$-\$\$	1-2 gm q 12h	Infectious Diseases Service approval
Cefotaxime	\$\$-\$\$	1-2 gm q 8h	Unrestricted
Cefoxitin	\$\$-\$\$\$	1-2 gm q 6-8h	Pediatrics, patients with coagulopathies, single dose usage
Ceftazidime	\$\$-\$\$\$	1-2 gm q 8h	Infectious Diseases Service approval
Ceftriaxone	\$	1 gm q 24h	Unrestricted
Cefuroxime	\$	1.5 gm q 8h	Infectious Diseases , Pulmonology, Pediatrics, Cardiothoracic Surgery
Ciprofloxacin	\$	400 mg q 12h	Unrestricted
Clindamycin	\$\$\$	900 mg q 8h	Unrestricted
Daptomycin	\$\$\$\$\$	8 mg/kg q 24h	Infectious Diseases Service approval
Doripenem	\$\$\$\$\$	500 mg q 8h (4 hour infusion)	Infectious Diseases Service approval
Doxycycline	\$	100 mg q 12h	Unrestricted
Erythromycin	\$\$\$\$	500 mg q 6h	Unrestricted
Gentamicin	\$	7 mg/kg q 24h	Unrestricted
Levofloxacin	\$	500-750 mg q 24h	Unrestricted
Linezolid	\$\$\$\$\$	600 mg q 12h	Infectious Diseases Service approval
Meropenem	\$\$\$\$\$	1 gm q 8h	Infectious Diseases Service approval
Metronidazole	\$	500 mg q 6h	Unrestricted
Oxacillin	\$\$\$-\$\$\$\$\$	1-2 g q 6h	Unrestricted
Penicillin G	\$\$\$\$	2 million units q 4h	Unrestricted
Piperacillin/Tazobactam	\$\$\$	3.375 gm q 8h (4 hour infusion)	Infectious Diseases Service approval
Rifampin	\$\$\$	600 mg q 24h	Unrestricted
Tigecycline	\$\$\$\$\$	50 mg q 12h	Infectious Diseases Service approval
TMP/SMX	\$\$\$	15 mg TMP/kg/d q 6h	Unrestricted
Tobramycin	\$	7 mg/kg q 24h	Unrestricted
Vancomycin	\$\$	1 gm q 12h	Treatment of known or suspected methicillin resistant <i>Staphylococcus aureus</i>

*Daily Cost Codes per day of therapy: \$=<=\$15, \$\$=\$16-\$30, \$\$\$=\$31-\$45, \$\$\$\$=\$46-\$60, \$\$\$\$\$= >=\$61
 (daily costs include pharmacy preparation costs)

LAC+USC Medical Center

County of Los Angeles

2053 Marengo Street
 Los Angeles, California 90033

Antibiogram

January 2009-December 2009

Paul D. Holtom, M.D.
 Hospital Epidemiologist
 Chair, Pharmacy & Therapeutics Committee

Sanford Melnick, Pharm.D.
 Director, Pharmacy Services

Ira Shulman, M.D.
 Director, Laboratory & Pathology

Melanie Osby, M.D.
 Director, Microbiology Laboratory

Veena Venugopalan, Pharm.D.
 Infectious Diseases Service Pharmacist

Arthur Musashi, Pharm.D.
 Medication Use Review Pharmacist